You have 9 free searches left this month | for more free features.

hormone-refractory prostate adenocarcinoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide

Not yet recruiting
  • Prostate Adenocarcinoma
  • +2 more
  • Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
  • Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 4, 2023

Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8 Trial in Houston (drug,

Completed
  • Prostate Adenocarcinoma
  • +4 more
  • Abiraterone Acetate
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

Hormone-Resistant Prostate Cancer, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Tumor in the Soft Tissues Trial

Active, not recruiting
  • Hormone-Resistant Prostate Cancer
  • +6 more
  • Pembrolizumab
  • pTVG-HP Plasmid DNA Vaccine
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Nov 8, 2022

Refractory Cancer Trial in Hamburg (BIBW 2992 (Afatinib))

Terminated
  • Refractory Cancer
  • BIBW 2992 (Afatinib)
  • Hamburg, Germany
    University Medical Center Hamburg-Eppendorf
Jun 29, 2022

Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma, Hormone-refractory Prostate Cancer Trial in United

Active, not recruiting
  • Prostate Carcinoma Metastatic to the Bone
  • +2 more
  • Birmingham, Alabama
  • +5 more
Feb 10, 2021

Hormone-refractory Prostate Cancer Trial (AMX-500)

Not yet recruiting
  • Hormone-refractory Prostate Cancer
  • (no location specified)
Aug 11, 2023

Metastatic Hormone Refractory Prostate Cancer Trial in Saint Louis (Cabozantinib, Nivolumab, Abiraterone acetate)

Recruiting
  • Metastatic Hormone Refractory Prostate Cancer
  • Saint Louis, Missouri
    Washington University School of Medicine
Jun 6, 2022

Prostate Cancer, Prostate Adenocarcinoma Trial in Charlotte (ADT+Docetaxel+Enzalutamide)

Active, not recruiting
  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Charlotte, North Carolina
    Levine Cancer Institute
Jan 12, 2023

Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy Trial in France (Abiraterone)

Completed
  • Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
  • Bordeaux, France
  • +4 more
May 18, 2022

Prostate Adenocarcinoma Trial in Duarte (drug, radiation, other)

Recruiting
  • Prostate Adenocarcinoma
  • Leuprolide Acetate
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Sep 14, 2022

Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone Trial in Houston (Abiraterone

Active, not recruiting
  • Metastatic Prostate Carcinoma
  • +5 more
  • Abiraterone Acetate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 26, 2022

Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Metastatic Prostate Carcinoma Trial in Seattle

Active, not recruiting
  • Castration-Sensitive Prostate Carcinoma
  • +7 more
  • Antiandrogen Therapy
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 8, 2022

PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7 Trial in Duarte, South Pasadena (drug, radiation, other)

Active, not recruiting
  • PSA Level Greater Than Two
  • Stage IV Prostate Adenocarcinoma AJCC v7
  • Duarte, California
  • +1 more
Apr 4, 2022

Metastatic Malignant Tumor in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7 Trial in

Active, not recruiting
  • Metastatic Malignant Neoplasm in Lymph Node
  • +3 more
  • Antiandrogen Therapy
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 3, 2022

Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

Not yet recruiting
  • Androgen-Independent Prostatic Cancer
  • +8 more
  • lorigerlimab
  • +2 more
  • (no location specified)
May 4, 2023

Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8 Trial in Philadelphia

Recruiting
  • Prostate Adenocarcinoma
  • +2 more
  • MRI-guided Intensity-Modulated Radiation Therapy
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 4, 2023

Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression Trial in Portland (drug, other,

Active, not recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Sep 26, 2022

Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8 Trial in Los Angeles (drug,

Not yet recruiting
  • Prostate Adenocarcinoma
  • +3 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Oct 5, 2023

Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +7 more
  • Biopsy
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Stage IV Prostate Adenocarcinoma AJCC v7 Trial in Worldwide (drug, other, procedure)

Recruiting
  • Stage IV Prostate Adenocarcinoma AJCC v7
  • Antiandrogen Therapy
  • +5 more
  • Duarte, California
  • +15 more
Jan 24, 2023

Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Trial in Baltimore (Ipilimumab, Nivolumab,

Completed
  • Prostate Cancer
  • +2 more
  • Ipilimumab
  • +2 more
  • Baltimore, Maryland
    Johns Hopkins University/Sidney Kimmel Cancer Center
Jan 6, 2022

Prostate Cancer Trial in United States (Vinflunine)

Completed
  • Prostate Cancer
  • Fort Myers, Florida
  • +11 more
Dec 14, 2021

Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma Trial in United States (Sacituzumab Govitecan-hziy (SG))

Completed
  • Gastric Adenocarcinoma
  • +15 more
  • Sacituzumab Govitecan-hziy (SG)
  • Aurora, Colorado
  • +11 more
Aug 10, 2021

Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy

Active, not recruiting
  • Hormone-Resistant Prostate Cancer
  • +3 more
  • Laboratory Biomarker Analysis
  • Quality-of-Life Assessment
  • Scottsdale, Arizona
  • +2 more
Feb 3, 2022